Digoxin (0.25mg)

DRUG2 trials

Sponsors

Advenchen Laboratories, LLC, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Conditions

Alveolar Soft Part SarcomaHealthyLeiomyosarcomaSoft-Tissue SarcomaSynovial Sarcoma

Phase 1

Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates

CompletedNCT05064488

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyHealthy

Start: 2021-10-04End: 2021-12-10Updated: 2025-12-05

Phase 3

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

RecruitingNCT03016819

Advenchen Laboratories, LLCAlveolar Soft Part Sarcoma, Leiomyosarcoma, Soft-Tissue Sarcoma +1

Start: 2017-08-15End: 2028-12-01Target: 325Updated: 2026-02-25

Related Papers

A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).

Journal of Clinical Oncology2025-05-281 citations

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma.

Journal of Clinical Oncology2021-05-2025 citations